🔗 Share this article

As the United States undertakes unprecedented changes to its vaccine schedules, a particular individual appears somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccines in the global health crisis and has focused upon alleged fatalities following COVID-19 vaccination in her brief tenure at the FDA.

Scheduled Overhauls to Childhood Vaccine Program

Public health authorities had intended to announce sweeping changes to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US out of alignment with many the global community with no evidence for public health gain. The planned update has been delayed until the new year.

Instead of the director of the vaccine center, Dr. Høeg is set to present at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to run the center this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the agency – and it signals a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Høeg has frequently advocated for discontinuing some pediatric shot schedules in the US to become more like Denmark's approach, a country with comprehensive healthcare and a number of inhabitants approximately the population of Wisconsin’s.

In her initial statements, she has continued to focus on immunizations – usually the responsibility of Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Doubts Over Background

The appointee has no apparent track record in medication creation, regulation or administrative roles, which has been standard for previous leaders of the CBER. She has served at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She appears not to have the necessary background” for running the CDER, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in managing a major agency. She is not an expert in pharmaceutical oversight.”

Previous directors of CBER would “grasp legal statutes and the underlying principles of drug development”, said Janet Woodcock. “Clearly, she has not acquired the sort of resume that previous people who headed CBER have had.”

The drug center has an vast portfolio at the agency, the former commissioner emphasized.

“Everybody just focuses on the new drug program, but the generic drug division approves thousands of generic medications. There’s a biosimilars division, over-the-counter program and other areas, and each of these have to be looked after,” Woodcock said. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership aspect to the role, which oversees over 5,000 personnel. “It’s a massive administrative position, if you do it right,” Woodcock said.

Agency Reaction and Disputed Programs

Regarding inquiries about Høeg’s fitness for the role and whether this appointment indicates increased cooperation among agency officials on vaccines, a spokesperson said that the “concerns are based on flawed presumptions”.

“Her experience is consistent with the duties of her role,” the representative said, citing the period Høeg spent guiding the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg inherits the agency head's new priority voucher program, a disputed expedited drug-approval program that reportedly troubled her preceding directors. “By what process are these therapies being picked for this voucher program? Who is making the decisions?” Dr. Howard said. “There’s a lot of secrecy occurring at the FDA right now.”

In general, he said, “the Food and Drug Administration looks to be trending towards laxer oversight of all drugs, except for vaccines.”

Public History on Vaccines

Concerning vaccines, Høeg has a more established, if concerning, past, Howard observe. She authored a study using non-validated volunteer-provided data to assess the rate of myocarditis after COVID-19 vaccination. She advised the Florida surgeon general Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “policy goals” for the new federal leadership included revising rules for new vaccines and halting “optional” immunizations, she said after the election on a podcast. At the FDA, Høeg has allegedly floated the idea of barring teenage boys from receiving Covid vaccines.

“She is an complete true believer who starts off with her preconceived notions and reverse-engineers to accommodate the science in a very deceptive, untruthful fashion,” Dr. Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|